Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How PTSA Tracers Simplify Cooling Water Treatment

A More Accurate and Safer Process Scale and corrosion in cooling tower systems can reduce heat transfer efficiency and cause unexpected equipment failures. While scale and corrosion inhibitors added to the water supply can minimize these occurrences, maintaining treatment levels within the control limits necessary to optimize performance and minimize costs can be a challenge. Let’s…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

A More Accurate and Safer Process

Scale and corrosion in cooling tower systems can reduce heat transfer efficiency and cause unexpected equipment failures. While scale and corrosion inhibitors added to the water supply can minimize these occurrences, maintaining treatment levels within the control limits necessary to optimize performance and minimize costs can be a challenge. Let’s take a look at a more accurate and safer process for controlling inhibitor levels over traditional methods.

The Traditional Method of Adding Inhibitor Products

Typically, inhibitor products are added to the tower water in direct proportion to the fresh water makeup. However, consistent inhibitor levels may not be maintained if the conductivity of the water makeup varies, there are multiple water supply sources, and/or treatment pumps lose prime. Using traditional feed methods under these conditions may lead to poor system control. Sometimes too little inhibitor is added, leading to cooling tower corrosion and scale formation that can impact system performance. Other times, too much inhibitor may be added, a wasteful practice that can leave deposits behind.

Fluorescent-Traced Product Feed and Control Systems

Fluorescent-traced product feed and control systems can help address these concerns. In this method, a colorless fluorescent dye called PTSA is added to the cooling water inhibitor, serving as a treatment level tracer. PTSA levels can be accurately measured in about 30 seconds using a handheld or in-line fluorometer, requiring no harmful chemical reagents. Unlike other tracers, such as molybdenum, PTSA is more environmentally friendly and is not typically subject to discharge restrictions.

Chem-Aqua’s aquaDART® Technology

Knowing when and where PTSA products should be applied ensures the success of an inhibitor treatment. That’s why Chem-Aqua performed extensive research into the limiting factors that must be considered when using PTSA. Our R&D, Product Management, and Equipment groups used the information they gathered to design our aquaDART® online monitoring, control, and chemical feed system for cooling towers.

Chem-Aqua’s aquaDART® technology allows for quick, accurate measurement of PTSA-based products. The system uses real-time sensors to directly measure key parameters to control scale and corrosion levels. When paired with a web-enabled controller, PTSA levels can be continuously monitored and adjusted to maintain them within 1% to 2% of the target concentration. The system can be board mounted for quick and accurate installation, and treatment levels can be easily verified using a hand-held meter.

aquaDART® Provides Precision Control

Safe, effective water treatment to control corrosion and scale in cooling tower systems is essential. The cutting-edge Chem-Aqua aquaDART® PTSA-traced product feed and control system is state-of-the-art automation for monitoring and controlling water treatment programs. aquaDART® helps facilities precisely control inhibitor levels and provides real-time alerts when levels are out of range, improving cooling tower performance while reducing water, energy, and labor costs.

To learn more, visit https://www.chemaqua.com/en-us/Services/Innovations/aquaDART-Automation-Control-Systems today.

Read more at chemaqua.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512